Opthea Limited announced the appointment of Timothy E. Morris as Chief Financial Officer (CFO), effective 24 October 2022. Mr. Morris is a veteran pharmaceutical executive based in the U.S. with extensive industry experience leading financial teams of public and private biotechnology companies. Mr. Morris' accomplishments include raising over $2.5 billion in equity and convertible securities for seven companies and the completion of over 95 transactions.

Mr. Morris has an extensive professional finance and accounting background in both public and private companies, including over 25 years in public biotechnology companies as CFO. He joins Opthea from Humanigen Inc. where he served as Chief Operating Officer/Chief Financial Officer since his appointment in August 2020. Previously, Mr. Morris was Chief Financial Officer of Iovance Biotherapeutics which raised over USD 1 billion in four offerings to fund expansion of the clinical development program, build manufacturing capability and to prepare for commercialization.

During that time, the market capitalization of IOVA increased five times in three years. Prior to IOVA, Mr. Morris was Chief Financial Officer of AcelRx Pharmaceuticals, VIVUS Inc., and Questcor Pharmaceuticals Inc. He is currently on the Board of Directors of DBV Technologies S.A., Aquestive Therapeutics, Humanetics Corporation and Univercells S.A. Mr. Morris earned his Bachelor of Science in Business from California State University, Chico.